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Abstract
Background. Older patients with back pain are
more likely to visit their general practitioner (GP)
and are more likely to be prescribed analgesics.
Objective. To assess analgesic use in older adults
with back pain in general practice.
Methods. The BACE study in the Netherlands is a
prospective cohort study. Patients (aged >55 years)
with back complaints were recruited when consult-
ing their GP or shortly thereafter. Measurements
took place at baseline and at 3- and 6-month follow-
up. For medication use, patients were asked if they
had used any medication for their back pain in the
previous 3 months and, if so, to specify the medica-
tion name, dosage used, frequency of usage, and
whether the medication was prescribed or pur-
chased over the counter.
Results. Of the 1,402 patients who were approached
to enter the study, 675 were included. Of these
patients, 484 (72%) reported medication use at base-
line. Nonsteroidal anti-inflammatory drugs (NSAIDs)
(57%) were more often used than paracetamol
(49%). Paracetamol was mostly obtained over the
counter (69%), and NSAIDs were mostly obtained
by prescription (85%). At baseline, patients with
severe pain (numerical rating scale score ≥7) used
more paracetamol, opioids, and muscle relaxants.
Patients with chronic pain (back pain >3 months)
used more paracetamol, while patients with a
shorter duration of pain used more NSAIDs. During
follow-up there was an overall decline in medication
use; however, at 3- and 6-month follow-up, 36%
and 30% of the patients, respectively, still used
analgesics.
Conclusions. In these older adults consulting their
GP with back pain, 72% used analgesics at baseline.
Despite a decrease in medication use during follow-
up, at 3 and 6 months a considerable proportion still
used analgesics.
Key Words. Back Pain; Analgesics; Older Adults
Introduction
Back pain is a major health problem with a reported
lifetime prevalence of up to 84% [1]. In the Netherlands,
about 30–45% of patients with back pain visit their general
practitioner (GP) [2,3]. A recent study in the UK showed
that older patients (>70 years) with low back pain are more
likely to visit their GP and more likely to receive analgesics
compared with younger adults with back pain [4]. With
regard to analgesic options, international guidelines for
low back pain usually recommend paracetamol as first
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choice, followed by nonsteroidal anti-inflammatory drugs
(NSAIDs) [5]. Selecting analgesic medication for back pain
is important, not only for effective pain relief but also
because each class of medication is associated with par-
ticular (serious) adverse reactions, especially in older
adults.
NSAIDs, for example, are associated with adverse reac-
tions such as gastrointestinal and cardiovascular events
[6,7]. An Australian study reported that since NSAIDS
such as ibuprofen became available “over the counter,”
fewer people were using them appropriately and accord-
ing to the instructions [8]. Three percent of patients par-
ticipating in the study used more than the maximum dose
of NSAIDs, 7.5% used more than one NSAID, and 13%
were at risk of an interaction with another medication that
they took.
Adverse reactions from opioids are most commonly dry
mouth, nausea, vomiting, dizziness, and constipation
[9,10]. Dizziness can cause increased incidence of falls
and fractures [11,12]. A frequently used opioid, codeine,
can even elevate risk of all-cause mortality after only 30
days’ usage [13].
Most studies on analgesic use only report prescribed
medication [14–16]. This can give a wrong impression of
medication use, because paracetamol and NSAIDs are
often used without prescription. Furthermore, previous
studies assessing analgesic use in older adults were
mostly performed in settings other than general practice
[4,17,18], and most of these studies were cross-sectional
[4,16,19]. In the present study we examine both “over-
the-counter” and prescribed analgesic use in older adults
with back pain in general practice. Medication use was
assessed over 6 months of follow-up and compared
between patients with (1) different ages (55–74 years
vs ≥75 years), (2) different durations of pain (<3 months
vs ≥3 months), and (3) different pain scores for baseline
severity of back pain (<7 vs ≥7; range 0–10).
Methods
The Back Complaints in the Elders (BACE) study in the
Netherlands is a prospective observational cohort study.
Patient inclusion (N = 675) took place between March
2009 and September 2011 in a representative sample
of 49 general practices around Rotterdam. Patients
aged >55 years were recruited when they consulted a GP
with a new episode of back complaints. Back complaints
were defined as pain in at least a part of or the whole
region from the top of the shoulder blades to the first
sacral vertebra, with or without pain radiation to the leg. If
a patient had not visited a GP with the same back com-
plaints in the preceding 6 months, it was considered a
new episode. Patients were invited to participate in the
study by their GP during the consultation or in writing
within 2 weeks after the consultation.
Patients were excluded if they were unable to fill out the
questionnaires due to cognitive impairment or were not
able to read and write in Dutch. Patients who were unable
to undergo physical examination (e.g., wheelchair-bound
patients) were also excluded.
The Medical Ethics Committee of Erasmus University
Medical Center, Rotterdam, approved the study protocol.
Details of the BACE study design are described elsewhere
[20].
Data Collection
Baseline measurement included a questionnaire and physi-
cal examination of the back. Follow-up measurements took
place at 3 and 6 months post-baseline by means of ques-
tionnaires. The questionnaires asked about patient charac-
teristics, features of the back complaint, and use of pain
medication. Patients’ perceived severity of back pain aver-
aged over the previous week was measured on an 11-point
numerical rating scale (NRS) [21], with 0 as “no pain” and
10 representing “worst pain imaginable.” Disability was
measured with the Roland–Morris Disability Questionnaire
(RDQ) [22]. RDQ scores can range from 0 (no disability) to
24 (severe disability). Quality of life was measured with the
Dutch version of the Short Form—36 (SF-36) [23]. The
SF-36 measures eight dimensions: physical function,
physical role function, bodily pain, general health, vitality,
social function, emotional role function, and mental health.
Scores on these eight dimensions can be summarized by
two summary scores: a physical component summary
score and a mental component summary score. Each
dimension and summary score is scored from 1 to 100,
with a higher score representing better health [24,25].
Summary scores were calculated with adapted Z-values in
view of the higher mean age of our study population [23].
Depression was measured with the Center for Epidemio-
logic Studies Depression Scale (range 0–60). Patients
with a higher score are more prone to depression [26].
Pain catastrophizing was measured with the Pain
Catastrophizing Scale (range 0–52), with a higher score
representing a higher risk for catastrophizing [27]. Patients’
beliefs about their back pain were investigated with the
Back Beliefs Questionnaire (range 9–49), with a higher
score representing more positive thoughts on recovery
[28]. Lifestyle factors assessed included smoking habits
(yes/no) and alcohol consumption. Alcohol consumption
was measured with the Alcohol Use Disorders Identification
Test – Consumption questions [29,30]. Women were
defined as possible hazardous drinkers if they scored ≥3 on
the scale, men if they scored ≥4. During physical examina-
tion, body weight and height were measured and con-
verted to body mass index (BMI).
For medication use, patients were asked if they had used
any medication for their back pain in the previous 3
months and, if so, to specify the medication name, used
dosage, frequency of usage, and whether the medication
was prescribed or purchased as “over-the-counter” medi-
cation. The exact question asked is shown in the Appen-
dix. The medications reported by the patients were
recorded in a database and classified by an MD by
group: paracetamol, NSAID, opioid, muscle relaxant,
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antidepressant, anticonvulsant, and other. Nonphar-
macologic treatments were also recorded; patients were
asked if they had visited their GP, physiotherapist, or
medical specialist in the past 3 months.
Statistical Analysis
Descriptive statistics are used to present patient and
back complaint characteristics in patient counts for all
variables with categorical data and as mean and stan-
dard deviation (SD) for continuous variables. Patients
using medication for back pain at baseline were com-
pared with the patients not using any medication for their
back pain. For continuous variables, an independent-
sample t-test was used. Variables with categorical data
were analyzed using the chi-square test. If >20% of the
cells contained an expected count of <5, a Fisher’s
exact test was performed. Patients using medication for
back pain at baseline, 3 months, or 6 months were
selected, and medication use was further analyzed.
Patient counts were used to describe which medication
types were most commonly used and the frequency of
medication use.
Patients using medication were divided into groups
according to age (>55–74 years vs ≥75 years), to whether
pain was acute or chronic (<3 months vs >3 months), and
to the severity of back pain at baseline (NRS <7 vs
NRS ≥7). Differences were analyzed using the chi-square
test. If >20% of the cells contained an expected count
of <5, a Fisher’s exact test was performed. Reported P
values were from two-sided tests, and a P value < 0.05
was defined as statistically significant. All analyses were
performed using SPSS software (version 20 for Windows,
Chicago, IL, USA).
Results
Figure 1 shows that 1,402 patients were invited to
participate and that 675 patients were eventually
included.
Characteristics of all patients included in the BACE study
are presented in Table 1. Mean age was 66 ± 7.6 years,
and 274 of the patients were male (41%). For all included
patients, the mean severity of baseline back pain was
5.2 ± 2.7 (NRS). Pain severity was higher in patients using
pain medication at baseline compared with those who did
not use analgesics for their back pain (5.5 ± 2.7 vs
4.4 ± 2.4 respectively). For 87 patients (13%), this episode
of back pain was the first in their life. Mean disability
measured with the Roland–Morris Disability Questionnaire
was 9.8 ± 5.8; disability score was higher in patients using
analgesics for their back pain compared with those who
did not take analgesics (10.6 ± 5.7 vs 7.7 ± 5.6, respec-
tively). Chronic back complaints (duration >3 months)
were reported by 156 patients (23%). Patients who did
use pain medication were less likely to have chronic back
complaints compared with those who did not use analge-
sics. Furthermore, patients using pain medication for their
Patients invited to participate (N = 1402)
- A: Directly during consultation (N = 141)
- B: In writing after consultation (N = 1261)
Reasons for exclusion (N = 727):
- Patients not willing to participate (N = 291)
- Patients did not meet inclusion criteria (N = 118)
- Reason unknown (N = 318)
Inclusion (N = 675)
- Via A: direct during consultation (N = 105)
- Via B: In writing after consultation
   (N = 570)
Lost to follow-up (N = 13):
- No longer interested to participate (N = 5)
- Diseased (N = 1)
- Cognitive impairment (N = 1)
- Health issues (N = 1)
- Reason unknown (N = 5)
Baseline measurements (N = 675)
- Returned questionnaire (N = 667)
- Physical examination (N = 670)
3-month follow-up (N = 662)
- Returned questionnaire (N = 626)
- Missing (N = 36)
Lost to follow-up (N = 8):
- No longer interested to participate (N = 3)
- Reason unknown (N = 5)
6-month follow-up (N = 654)
- Returned questionnaire (N = 611)
- Missing (N = 43) Figure 1 Flowchart of patient
inclusion.
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back pain had a lower mean quality of life on the SF-36
physical summary scale, scored higher regarding pain
catastrophizing, and had less positive thoughts regarding
recovery.
Out of all patients, 72% (484 patients) reported using pain
medication in the 3 months prior to baseline (Table 2). In
patients using analgesics, NSAIDs (57%) were more often
used than paracetamol (49%). Most patients (69%) using
paracetamol purchased it over the counter, while NSAIDs
were more frequently obtained via a prescription (85%). A
relatively large proportion of the patients used opioids
(17%), and 8% used muscle relaxant. Used opioids were
morphine, codeine, and tramadol. The muscle relaxants
were mostly benzodiazepines (92%). Overall, the fre-
quency of taking pain medication was mostly daily (67%);
only a small proportion (7%) of all medication was used
less than once a week. Most patients (49%) used one kind
of medication; 120 patients (18%) used two types, and
only 35 patients (5%) used three types (Figure 2). Medi-
cations reported in the “other” category were hydrocorti-
sone (2 patients), NSAID cream (2 patients), glucosamine
(2 patients), homeopathic cream (2 patients), nefopam
(1 patient), Harpagophytum procumbens (1 patient), and
menthol gel (1 patient).
At 3-month follow-up, medication use was lower com-
pared with baseline (Table 2). Of the 245 patients (36%)
using medication at 3-month follow-up, 214 also used
medication at baseline. At 3-month follow-up,
paracetamol was used more often than NSAIDs (51% vs
43%). Although most patients still used analgesics on a
daily basis, this proportion (56%) was smaller compared
with baseline (67%). At 3-month follow-up, paracetamol
had been obtained over the counter by 84 patients (67%),
and NSAIDs were obtained by prescription by 82 patients
(77%). Nevertheless, among medication users, 178 (73%)
reported the use of one type of analgesic (Figure 2). At
3-month follow-up medications reported in the “other”
category were glucosamine (2 patients), prednisone (2
patients), hydroxychloroquine (1 patient), cold cream
(2 patients), NSAID cream (1 patient), and menthol cream
(1 patient).
At 6-month follow-up there was a further (albeit small)
decline in medication use (204 patients; 30%) (Table 2).
Table 1 Baseline characteristics of the patients in the BACE study
All Patients
(N = 675)
Patients Using
Pain Medication
(N = 484)
Patients Not Using
Pain Medication
(N = 191) P Value
Age in years, mean ± SD 66 ± 7.6 66 ± 7.7 66 ± 7.6 0.58
Male, N (%) 274 (41) 188 (39) 86 (45) 0.14
BMI, mean ± SD 27.5 ± 4.7 27.3 ± 4.7 27.9 ± 4.7 0.19
Low education level, N (%) 279 (41) 205 (42) 74 (39) 0.57
Smoking, N (%) 122 (18) 87 (18) 35 (18) 0.80
Hazardous drinking, N (%)* 333 (49) 242 (50) 91 (48) 0.88
Severity of back pain, mean ± SD† 5.2 ± 2.7 5.5 ± 2.7 4.4 ± 2.4 < 0.001
Disability, mean ± SD‡ 9.8 ± 5.8 10.6 ± 5.7 7.7 ± 5.6 < 0.001
First episode of back pain, N (%) 87 (13) 61 (13) 26 (14) 0.69
Duration of back pain >3 months, N (%) 156 (23) 104 (21) 52 (27) 0.04
Pain radiates to below the knee, N (%) 205 (30) 155 (32) 50 (26) 0.20
Pain location only lumbar, N (%) 450 (67) 313 (65) 137 (72) 0.19
Quality of life physical summary scale, mean ± SD§ 43.2 ± 8.9 41.7 ± 8.5 47.2 ± 8.8 < 0.001
Quality of life mental summary scale, mean ± SD§ 49.6 ± 10.3 49.8 ± 10.4 48.9 ± 9.9 0.32
Depressive symptoms, mean ± SD¶ 10.0 ± 7.8 10.3 ± 7.8 9.2 ± 7.7 0.09
Pain catastrophizing, mean ± SD** 14.1 ± 10.6 15.1 ± 10.8 11.5 ± 9.5 < 0.001
Attitude and beliefs about back pain, mean ± SD†† 26.4 ± 7.2 25.8 ± 7.2 28.0 ± 7.1 0.001
* Hazardous drinking is measured with Alcohol Use Disorders Identification Test—Consumption: range 0–12; ≥3 in woman and ≥4
in men is risk of hazardous drinking [29,30].
† Measured with a numerical rating scale as an average of the previous week; range 0–10; 0 indicates no pain, 10 indicates the
worst pain imaginable.
‡ Measured with the Roland–Morris disability questionnaire; range 0–24; zero indicates no disability [22].
§ Measured with the Short Form-36, range 0–100; higher score indicates higher quality of life [23–25].
¶ Measured with the Center for Epidemiologic Studies Depression Scale, range 0–60; higher score indicates more prone to
depression [26].
** Measured with Pain Catastrophizing Scale, range 0–52; higher score indicates more risk for catastrophizing [27].
†† Measured with Back Beliefs Questionnaire, range 9–49; higher score indicates more positive thoughts of recovery [28].
Missing values ranged from 0% to 12%.
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The frequency of medication use at 6-month follow-up
was similar to the usage at 3-month follow-up. Other
medications reported at 6-month follow-up were glu-
cosamine (2 patients), prednisolone (1 patient), and
NSAID cream (4 patients).
Of the 484 patients who reported use of pain medication
for their back pain at baseline, 146 patients still reported
use of pain medication at 3- and 6-month follow up. Of the
191 patients not using pain medication at baseline, 31 had
started using pain medication for their back pain at
3-month follow-up. Of these 31 patients, 11 patients still
used pain medication at 6-month follow-up.
Among patients using paracetamol at baseline, 7% also
reported use of paracetamol at 3- and 6-month follow-up.
A similar percentage was found in patients reporting
NSAID use. Of these patients, 14 reported daily use of
paracetamol and 9 reported daily use of NSAIDs. Also, 15
patients (2%) reported opioid use at all three measure-
ment points, 7 of whom reported daily use.
Medication use at baseline was compared between the
age groups (Table 3). Paracetamol was more often used
by patients aged ≥75 years (60%) compared with relatively
younger patients (46%), while NSAIDs were more often
used by patients aged 55–74 years (61% vs 40%).
Patients with severe back pain (NRS ≥7) more often used
paracetamol, opioids, and muscle relaxants. Patients with
chronic pain (≥3 months) more often used paracetamol
(58% vs 45%), while patients with acute complaints more
often used NSAIDs (61% vs 43%).
At 3-month follow-up, there were no longer any differ-
ences between the age groups in analgesic usage.
However, patients with severe back pain (NRS ≥7) at
baseline still more often used opioids (27% vs 14%) and
muscle relaxants (7% vs 2%) at 3-month follow-up
compared with patients with less severe back pain.
At 6-month follow-up, no difference in muscle relaxant
usage was reported; however, opioids were still used more
often by patients with severe back pain at baseline com-
pared with those with less severe back pain at baseline.
Fifty-four percent of all patients also reported at least one
(additional) visit to their GP, a physiotherapist, or a medical
specialist in the 6 months after baseline. Of the 484
patients reporting medication use at baseline, 33% visited
their GP vs 22% of the patients who did not use analge-
sics at baseline (P < 0.001), and 40% of the 484 visited a
physiotherapist; in the patients who did not use medica-
tion at baseline, the rate was 69% (p 0.74). Medical spe-
cialists were visited by 17% of the patients taking
medication at baseline and by 8% of those who did not
use any medication at baseline (P < 0.01).
Discussion
Summary of Results
The present study explores over-the-counter and pre-
scribed analgesic use in older adults with back pain in
general practice; ≥70% of these patients reported the use
of analgesics. Medication use declined during the 6
months post-baseline. At baseline, NSAIDs were more
often used by the relatively younger patients (55–74
years); this may indicate that GPs take into account pos-
sible adverse drug reactions related to NSAIDs, especially
among older adults. Nevertheless, 40% of those
aged ≥75 years used NSAIDs at baseline and at 3- and
6-month follow-up. Patients with severe back pain at
baseline more frequently used paracetamol, opioids, and
muscle relaxants at baseline and at 3-month follow-up
Figure 2 Number of types of
medications used by the patients
during the study period. Numbers
on top of bars are percentages.
Line indicates total of patients
using at least one type of pain
medication.
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compared with patients with less severe pain at baseline;
there was no difference in NSAID use between these
groups. All differences in medication use between the age
groups and between groups with different durations of
complaints had disappeared at 3 months post-baseline.
Interpretation of Findings
Previous studies reported that NSAIDs are the most often
prescribed medication for low back pain [16,31]; however,
these studies did not take into account over-the-counter
medication. We hypothesized that because patients fre-
quently use over-the-counter paracetamol, it was prob-
ably underrepresented in these types of studies. However,
the present study showed that (at baseline) NSAIDs were
the most frequently used analgesics in older patients
(85% obtained by prescription and 11% over the counter).
During the study period, paracetamol was mostly
obtained over the counter (69%). The Dutch guidelines for
acute low back pain recommend that when medication is
prescribed, it should be done on a time contingency basis,
with paracetamol as first-choice medication. If there is
insufficient pain relief with paracetamol alone, the second
step is the use of NSAIDs [32,33]. This is in line with
international guidelines [5]. However, patients in the
present study most often used NSAIDs, which may not be
in line with guideline recommendations. For patients with
chronic back pain, the Dutch and European guidelines
recommend NSAIDs and (weak) opioids for short-term
pain relief [32–34]. The European guideline complements
this with the recommendation to consider antidepressants
as comedication [34]. In the present study, most patients
with chronic pain at baseline used paracetamol, followed
by NSAIDs and then by opioids. Antidepressants were
used by very few patients (2%) with chronic back pain. In
the present study, because details on comorbidity,
comedication and other considerations possibly taken
into account by the GPs were unknown, it is difficult to
draw conclusions about whether analgesic use was in line
with current guideline recommendations.
The finding that over 70% of our patients consulting their
GP reported use of analgesics is similar to that of Cherkin
et al., who reported that about 80% of patients used
medication after visiting their GP [31]. Cherkin et al. also
reported a similar (but slightly greater) decrease; after 7
weeks, only 13% of their patients used any medication,
whereas in our study, after 3 months, 36% of the patients
reported analgesic usage. However, patients in the study
of Cherkin et al. were younger (mean age 43 years) than
our study population.
In a study by Luo et al., older adults (≥65 years) were also
less likely to be prescribed traditional NSAIDs compared
with younger patients, while there was no prescription
difference in cyclooxygenase-2 (COX-2) inhibitors [15].
Federman et al. found that patients aged ≥75 years in an
outpatient setting were more likely to use NSAIDs, but
mostly used COX-2 inhibitors [14]. However, Federman
et al. excluded patients with a contraindication for
NSAIDs, which might explain the difference compared
with the study of Luo et al. and with the present study.
Federman et al. also reported that opioids were less fre-
quently used by older adults [14], whereas we found no
difference in opioid use between our younger and older
age categories.
An Australian study in the open population found that
analgesics (opioids and combination analgesics) were
more often used in those with the highest scores for low
back pain [35].
Another study showed that patients (in primary and sec-
ondary care settings) with chronic low back pain who
reported increased severity of back pain had increased
numbers of prescriptions for opioids and decreased
numbers of prescriptions for NSAIDs [18]. This is similar to
our finding that there was no difference in NSAID use
between the subgroups, while there was a difference in
opioid use between the subgroups.
Older patients with back pain are more likely to be pre-
scribed analgesics than younger patients [4,16]. This is
remarkable, because older patients are more prone to
adverse drug reactions, especially in the case of
comedication or of comorbidities such as liver or kidney
failure. An Australian study found that for over-the-counter
medication, 1.9% of paracetamol users and 23.1% of
ibuprofen users had contraindications for these analgesics
[36]. In another open population, it was shown that 10% of
older patients with low back pain used NSAIDs while they
were also using a diuretic and an angiotensin-converting
enzyme inhibitor or angiotensin II receptor antagonist [35];
such patients are at increased risk of acute renal failure
[37]. In our study population, we did not ask about other
types of medication use and therefore cannot judge
whether our patients were at risk for adverse drug reac-
tions. Also, because we did not ask about the analgesic
dose, we could not determine whether the dosage used
might potentially cause an adverse drug reaction. We did
record that 5 patients at baseline and 3 patients at
3-month follow-up used NSAIDs obtained both by pre-
scription and over the counter. However, because we
asked about medication use during the previous 3
months, we cannot evaluate whether these medications
were used simultaneously. Nevertheless, it should be
noted that patients are not always aware of the risks of
using over-the-counter medication [8].
Strengths and Limitations
We used questionnaires to ask patients which analgesics
they used for their back pain; this enabled us to report
on both prescribed and over-the-counter analgesics.
Although this provides more information than data derived
from medical records alone, there is a possibility of recall
bias. However, it has been reported that patients with
chronic disease (including low back pain) generally show
good concordance between self-reported medication use
and data in the patient’s medical record [38]. For ethical
reasons, we could not ask patients who did not participate
in the study any questions. Therefore, we could not make
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any comparisons between patients who did and did not
participate in the study regarding generalizability.
Conclusions
In this group of patients aged ≥55 years who consulted
their GP with back pain, 72% used analgesics at baseline,
paracetamol and NSAIDs being the most frequently used.
Although a decrease in medication use was seen during
follow-up, a substantial proportion of these older adults
still used analgesics at 3- and 6-month follow-up (36%
and 30%, respectively).
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Appendix: Question Regarding Used Medication
Did you use medication in the past 3 months for your back complaints, for example pain killers or muscle relaxants?
□ Yes; fill in below the name of the medication, how frequently you use it, and whether your medication was prescribed
or bought on your own initiative.
□ No
Medication Average Use Obtained
□ Medication name: □ lLess than 1 time per week □ Prescribed
□ 1–2 times per week □ Own initiative
□ 3–5 times per week
□ Daily
□ Medication name: □ Less than 1 time per week □ Prescribed
□ 1–2 times per week □ Own initiative
□ 3–5 times per week
□ Daily
□ Medication name: □ Less than 1 time per week □ Prescribed
□ 1–2 times per week □ Own initiative
□ 3–5 times per week
□ Daily
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